GYRE THERAPEUTICS, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Caldwell William S | SVP - Drug Discovery and Dev. | Sale | 315 | $24.00 | $7,560 | 7,735 | Apr 26, 2010 |
| Caldwell William S | SVP - Drug Discovery and Dev. | Option Exercise | 7,245 | $5.10 | $36,950 | 14,980 | Apr 20, 2010 |
| Caldwell William S | SVP - Drug Discovery and Dev. | Option Exercise | 36,946 | $5.10 | $188,425 | 44,681 | Apr 16, 2010 |
| Zorn Peter A | SVP, Lg Affrs, GC and Secrtary | Option Exercise | 313 | $5.10 | $1,596 | 313 | Mar 31, 2010 |
| SNYDERMAN RALPH | — | Option Exercise | 7,500 | $7.10 | $53,250 | 15,000 | Feb 16, 2010 |
| Bencherif Merouane | VP, Preclinical Research | Option Exercise | 19,926 | $5.55 | $110,589 | 73,108 | Jan 15, 2010 |
| Bencherif Merouane | VP, Preclinical Research | Sale | 7,735 | $20.81 | $160,965 | — | Jan 4, 2010 |
| Zorn Peter A | VP, Lg Affrs, GC and Secrtary | Sale | 312 | $21.30 | $6,646 | — | Dec 31, 2009 |
| Dunbar Geoffrey C | VP, Clin. Dev. & Reg. Affairs | Sale | 22,602 | $21.86 | $494,080 | 1,153 | Dec 16, 2009 |
| Bencherif Merouane | VP, Preclinical Research | Option Exercise | 15,532 | $8.51 | $132,177 | 23,267 | Dec 16, 2009 |
| deBethizy J Donald | President and CEO | Sale | 209,004 | $21.98 | $4,593,908 | — | Dec 16, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Sale | 23,201 | $21.93 | $508,798 | 7,735 | Dec 16, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Sale | 23,206 | $21.93 | $508,908 | 7,735 | Dec 16, 2009 |
| deBethizy J Donald | President and CEO | Sale | 2,600 | $22.44 | $58,344 | 44,317 | Dec 15, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Sale | 11,809 | $22.31 | $263,459 | 2,799 | Dec 15, 2009 |
| Bencherif Merouane | VP, Preclinical Research | Option Exercise | 4,967 | $8.51 | $42,269 | 20,670 | Dec 14, 2009 |
| Brennan Jeffrey P | VP - Bus. & Commercial Dev. | Option Exercise | 1,200 | $5.63 | $6,756 | 12,755 | Dec 11, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Sale | 37,223 | $21.53 | $801,411 | 2,799 | Dec 11, 2009 |
| Zorn Peter A | VP, Lg Affrs, GC and Secrtary | Option Exercise | 34,611 | $1.75 | $60,569 | 34,611 | Oct 22, 2009 |
| Brennan Jeffrey P | VP - Bus. & Commercial Dev. | Sale | 13,978 | $21.95 | $306,817 | — | Oct 20, 2009 |
| Zorn Peter A | VP, Lg Affrs, GC and Secrtary | Option Exercise | 19,187 | $1.75 | $33,577 | 23,650 | Oct 19, 2009 |
| BIOTECHNOLOGY VALUE FUND II LP | — | Sale | 108,000 | $23.60 | $2,548,800 | 2,435,925 | Oct 16, 2009 |
| Dunbar Geoffrey C | VP, Clin. Dev. & Reg. Affairs | Option Exercise | 11,000 | $1.75 | $19,250 | 34,755 | Sep 18, 2009 |
| Dunbar Geoffrey C | VP, Clin. Dev. & Reg. Affairs | Sale | 9,050 | $16.27 | $147,244 | 23,755 | Sep 16, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Option Exercise | 2,100 | $1.75 | $3,675 | 9,835 | Sep 4, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Sale | 8,000 | $15.07 | $120,560 | 2,799 | Sep 4, 2009 |
| Dunbar Geoffrey C | VP, Clin. Dev. & Reg. Affairs | Sale | 10,000 | $15.02 | $150,200 | 23,755 | Sep 4, 2009 |
| deBethizy J Donald | President and CEO | Sale | 851 | $15.00 | $12,765 | 46,917 | Sep 4, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Sale | 5,400 | $14.50 | $78,300 | 2,799 | Aug 31, 2009 |
| deBethizy J Donald | President and CEO | Sale | 9,400 | $14.54 | $136,676 | 46,917 | Aug 31, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Sale | 13,955 | $14.54 | $202,906 | 7,735 | Aug 31, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Option Exercise | 1,600 | $1.75 | $2,800 | 9,335 | Aug 28, 2009 |
| Dunbar Geoffrey C | VP, Clin. Dev. & Reg. Affairs | Sale | 2,100 | $14.00 | $29,400 | 23,755 | Aug 28, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Sale | 1,600 | $14.00 | $22,400 | 7,735 | Aug 28, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Option Exercise | 2,500 | $1.75 | $4,375 | 5,299 | Aug 24, 2009 |
| deBethizy J Donald | President and CEO | Sale | 2,400 | $13.52 | $32,448 | 46,917 | Aug 24, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Option Exercise | 4,500 | $1.75 | $7,875 | 7,299 | Aug 14, 2009 |
| deBethizy J Donald | President and CEO | Option Exercise | 4,600 | $1.75 | $8,050 | 51,517 | Aug 14, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Option Exercise | 4,595 | $2.93 | $13,463 | 14,515 | Aug 11, 2009 |
| Brennan Jeffrey P | VP - Bus. & Commercial Dev. | Option Exercise | 15,000 | $1.75 | $26,250 | 15,000 | Aug 10, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Option Exercise | 771 | $1.75 | $1,349 | 8,506 | Aug 7, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Option Exercise | 5,700 | $1.75 | $9,975 | 8,499 | Aug 7, 2009 |
| deBethizy J Donald | President and CEO | Sale | 2,850 | $12.04 | $34,314 | 46,917 | Aug 7, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Sale | 1,300 | $12.00 | $15,600 | 2,799 | Jul 29, 2009 |
| deBethizy J Donald | President and CEO | Sale | 4,400 | $11.05 | $48,620 | 48,217 | Jul 29, 2009 |
| Caldwell William S | VP - Drug Discovery and Dev. | Sale | 693 | $12.00 | $8,316 | 7,735 | Jul 29, 2009 |
| deBethizy J Donald | President and CEO | Sale | 2,600 | $11.01 | $28,626 | 46,917 | Jul 28, 2009 |
| Musso Alan A | VP, CFO & Treasurer | Option Exercise | 3,037 | $1.75 | $5,315 | 5,836 | Jul 28, 2009 |
| Bencherif Merouane | VP, Preclinical Research | Sale | 41,213 | $10.39 | $428,203 | 7,735 | Jul 28, 2009 |
| Bencherif Merouane | VP, Preclinical Research | Option Exercise | 5,314 | $5.10 | $27,101 | 45,280 | Jul 27, 2009 |